Company Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer.
It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer.
BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
| Country | United States |
| IPO Date | Dec 16, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Dr. Jay M. Short Ph.D. |
Contact Details
Address: 11085 Torreyana Road San Diego, California United States | |
| Website | https://www.bioatla.com |
Stock Details
| Ticker Symbol | BCAB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001826892 |
| CUSIP Number | 09077B104 |
| ISIN Number | US09077B1044 |
| Employer ID | 85-1922320 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jay M. Short Ph.D. | Co-Founder, Chief Executive Officer & Chairman |
| Richard A. Waldron | Senior Vice President & Chief Financial Officer |
| Dr. Cathy Chang Ph.D. | Senior Vice President of Research & Development |
| Dr. Eric L. Sievers M.D. | Chief Medical Officer |
| Dr. Gerhard Frey Ph.D. | Senior Vice President of Technology Development |
| Lisa M. Pelton | Accounting Manager |
| Monica Sullivan | Senior Vice President of Intellectual Property & Contracts |
| Sheri Lydick | Chief Commercial Officer |
| Susie Melody | Senior Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | 424B5 | Filing |
| Dec 20, 2024 | 8-K | Current Report |
| Dec 20, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Nov 07, 2024 | 8-K | Current Report |
| Oct 02, 2024 | SC 13D/A | [Amend] Filing |
| Sep 23, 2024 | 8-K | Current Report |
| Sep 06, 2024 | SC 13D/A | [Amend] Filing |
| Sep 03, 2024 | 4 | Filing |